RNA · Atrium Therapeutics, Inc. · Insider Trading
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-09-18 | Gallagher Kathleen P. |
Director, See Remarks |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
Common Stock
|
11,632 |
| 2026-09-18 | Kenney Stephanie |
See Remarks |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
Common Stock
|
2,375 |
| 2026-09-18 | Boyce Sarah |
Director |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
Common Stock
|
126,418 |
| 2026-09-18 | Flanagan W. Michael |
Director |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
Common Stock
|
22,812 |
| 2026-09-18 | Winslow Brendan R. |
Chief Financial Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
Common Stock
|
6,742 |
| 2026-09-18 | Younis Husam |
Chief Scientific Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
Common Stock
|
11,216 |
| 2026-09-18 | Hughes Steven George |
Chief Development Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
Common Stock
|
21,459 |
| 2026-09-18 | Hoyos Rocio Martin |
Chief Strategy Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
Common Stock
|
8,320 |
| 2026-04-20 | Hoyos Rocio Martin |
Chief Strategy Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
60,000 |
| 2026-04-20 | Hoyos Rocio Martin |
Chief Strategy Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Common Stock
|
30,000 |
| 2026-04-20 | Hughes Steven George |
Chief Development Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Common Stock
|
30,000 |
| 2026-04-20 | Winslow Brendan R. |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Common Stock
|
30,000 |
| 2026-04-20 | Hughes Steven George |
Chief Development Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
60,000 |
| 2026-04-20 | Gallagher Kathleen P. |
Director, See Remarks |
Award↑
Filing footnotes — Common Stock (Direct)
Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Common Stock
|
102,500 |
| 2026-04-20 | Kenney Stephanie |
See Remarks |
Award↑
Filing footnotes — Common Stock (Direct)
Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Common Stock
|
30,000 |
| 2026-04-20 | Winslow Brendan R. |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
60,000 |
| 2026-04-20 | Kenney Stephanie |
See Remarks |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
60,000 |
| 2026-04-20 | Gallagher Kathleen P. |
Director, See Remarks |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
205,000 |
| 2026-04-20 | Younis Husam |
Chief Scientific Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Common Stock
|
30,000 |
| 2026-04-20 | Younis Husam |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
60,000 |
| 2026-02-27 | WILSON TROY EDWARD |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
20,000 |
| 2026-02-27 | Skerjanec Simona |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
20,000 |
| 2026-02-27 | Boyce Sarah |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
20,000 |
| 2026-02-27 | BOESS CARSTEN |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
20,000 |
| 2026-02-27 | Flanagan W. Michael |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
20,000 |